Live News EQUITY FLASH M impact Nov 04, 2026, 09:11 PM UTC Relay Therapeutics Reports Q3 Net Loss Q3 operating expenses were USD 90.245 million. Net income was below zero, versus the IBES estimate. RLAY SquawkNews Desk